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psychoactive substances in Australia
Drug checking may need to play a part in future public health interventions1s has been reported previously in the Journal,
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doi: 10.5694/mja15.01058Aincreasingly prevalent in patients presenting to
hospital emergency departments. A further cluster of
11 patients showing confusing hallmarks of
sympathomimetic poisoning but no identifiable
substance presented to St Vincent’s Hospital in Sydney
over a public holiday weekend in April 2015. Also, the
start to the 2015e2016 summer festival season has
included multiple deaths and hospitalisations following
drug use at festivals, leading to calls for novel actions to
protect public health.2 Here, we take the opportunity
to describe a method of harmminimisation that has been
deployed in Europe and could potentially be deployed
locally to tackle this problem.
Monitoring new psychoactive substances
New psychoactive substances (NPS) are emerging
rapidly into the market, with more than 100 identified in
the past year by European monitoring systems.3 Existing
psychoactive drug monitoring systems have limited
capacity to identify NPS. Their limitations are detailed as
follows:
 self-reports (eg, household surveys and regular
interviews with sentinel groups, as reviewed by
Burns et al4) can identify what users think they
are taking, but not necessarily what they are actually
taking;
 web vendor monitoring (eg, analyses of surface
web and dark web [also see Burns et al4]) can
identify what vendors report they are selling, but
not what is actually sold; and
 pharmacological analyses (eg, wastewater analyses5)
can provide more accurate information about what
is actually being consumed, but not what
people believe they are consuming.
These monitoring systems have been used to identify NPS
and track their use in Australia, but they are not able to
characterise the congruency between what people believe
they are taking and what they are actually taking.
Combining all three of these methods and providing an
innovative drug-checking service would strengthen
surveillance of drugs being used in festival settings.
Accurate and tailored information can facilitate an open
dialogue between health care providers and drug users at
the point of consumption. Identifying emerging trends in
NPS will provide opportunities to prevent harm, and
enableour services to respondmoreeffectively to theharms
arising from both intentional and unintentional NPS use.144 MJA 204 (4) j 7 March 2016Drug-checking services
Several European countries now provide drug analysis
services,6 whereby individuals submit samples of their
drugs to have their contents identified and analysed for
purity. The results are provided to the consumer. The
analytical facility can be based either on-site (eg, at large
parties or festivals) or off-site. In some of the European
services, brief health interventions aimed at reducing
harm are offered to consumers simultaneously. Fast
turn-around drug analysis services may have reduced
harms resulting from recent episodes of mass
intoxications at festival settings by:
 identifying the NPS and other contents of the pills
or powders;
 monitoring NPS availability and use trends to
enable an effective public health response;
 identifying emerging hazards from specific NPS
and the formulations available;
 improving the knowledge base for effective clinical
management of acute and chronic presentations;
 providing an opportunity for users to seek help,
obtain health information to reduce potential
harms and to offer options for individual
behaviour change; and
 providing intelligence that could influence supply
dynamics.
The optimalmethod for providing analytical serviceswill
depend largely on the social and legal context. In Austria
and Switzerland, field workers from a non-government
organisation conduct on-the-spot drug analysis to
patrons at dance parties via a field laboratory equipped
with high-pressure liquid chromatography machines.
Samples are received directly from consumers and results
are available to themwithin 20 minutes, accompanied by
a brief intervention with referral if required.7 In the
United Kingdom, amnesty bins are placed in party
venues and a private, not-for-profit laboratory
undertakes the analyses to add to a library of NPS. In
larger nightclubs, on-site fieldworkers use infra-redmass
spectrometry to compare the drugs received with the
database. Local accords between police, public health
officials and the nightlife venue operators are required to
ensure successful integrated services. A network of 26
drug-checking sites in the Netherlands is incorporated
into the Ministry of Health as part of a national
surveillance system.8 This service offers immediate
results of quick office tests to potential users, with









Perspectivessamples are sent formore accurate spectrometric analysis,
and results are available within a week. Most
importantly, results are incorporated into the national
surveillance system and are monitored for trends in
emerging substances, and results are used to inform
public policy and practice. While the direct prevention of
deaths has not been documented, dangerous pills or
powders identified by checking systems in the
Netherlands have quickly disappeared from the Dutch
markets following the launch of warning campaigns.9
Discovering new compounds that endanger life is
unlikely to benefit the user after he or she has taken the
drug except in ruling out other causes for developing
severe syndromes. However, as more becomes known
about the psychopharmacology of specific compounds,
best-practice treatment algorithms can be created. If
backed up by a sensible brief intervention, such a service
might see users of drugs more engaged in caring for their
health, recognising problem substance use, and seeking
help. From a public health perspective, information on
new compounds can be used to monitor emerging trends




Several hurdles need to be overcome before drug checking
can be established in Australia. Drug sellers may view the
service as an opportunity to have their drugs checked
before they distribute them. As in Europe, drug-checking
services would need to ensure they are not complicit in
aiding drug distribution. There may also be a
misconception among users of the service that by having
theirdrugs“checked”, their use is condonedor seenas safe.
Existing drug-checking services deal with this
misconception through careful engagement with service
users to explain that all drug use is risky and that the only
completely safe option is to avoiddruguse. Thismessage is
more likely to be heeded by users of drug-checking
services who are receiving advice about harm reduction
that is individually tailored to their personal characteristics
and the known characteristics of the drugs they may
consume.
As happens overseas, Australian drug-checking services
will need to be provided in multiple sites in both
metropolitan and regional locations. Transport problems
would need to be solved to provide access to services
outside metropolitan areas.
Effective laboratory testing is expensive; without
adequate investment, the drug-checking service may be
restricted to ad hoc sites or subject to unreliable testing
techniques. Indeed, drug-checking interventions were
conducted in Australia over a decade ago,10 but, at that
time, on-site testing technology was restricted to colour
reagent test kits, which are not reliable enough nor able to
detect the larger number of substances currently
available. In 2016, for an investment of under $200 000
(based on the costs of a high-performance liquid
chromatography machine and employing a Scientist and
Drug andAlcohol Counsellor), a mobile laboratory couldbe set up and attached to existing peer-run harm-
reduction services, supported by existing full laboratories
providing in-kind support. While there are expenses
associatedwith the ongoing running of such a service, the
costs of trialling this kind of intervention are relatively
low with the use of currently available technology that
has been field-tested in other countries.
In addition, handling materials that are suspected of
being illegal substances is prohibited by law; there are
harm-reduction services currently operating in Australia
that have been provided with an exemption for service
staff and clients, such as Sydney’s medically supervised
injecting centre. Therefore, providing a drug-checking
service would not require a radical shift in national drug
policy, but would require cooperation between health
and police stakeholders.Conclusions
An important public health need inAustralia could bemet
byproviding an easily accesseddrug-checking service that
provides reliable and fast information to consumers about
the content of drugs, along with non-judgemental
harm-reduction advice. A further advantage is the ability
of such a service to track the appearance of NPS on the
market rapidly,8which ishelpful andsometimesnecessary
if we are to respondmore effectively to NPS-related harm.
Such a service could mitigate the severity and impact of
situations that commonly overwhelm emergency
departments around Australia by rapidly disseminating
information about NPS to (a) potential consumers,
warning them about specific products and batches, and
(b) clinicians, guiding them on the predicted toxidrome
and management of affected patients.
Concerns about the unintended consequences of
providing a drug-checking service include legitimisation
of the use of drugs, civil responsibility of the drug
checkers towards consumers of tested drugs, and the use
of the service by drug sellers as a quality control
mechanism. Such concerns have not been supported by
evidence in the European context.11 In Europe, the
service is used in tandem with opportunistic brief
interventions that provide a moment for education on
health and harm reduction, and reduces the delay to
treatment for problem drug use. Further experiencewith
services of this kind is required to ascertain the
feasibility, acceptability and effectiveness in inducing
behaviour change of various models of drug checking in
the Australian context, which is different from the Dutch
context (eg, there is no threat of prosecution for using
these drugs in the Netherlands). Therefore, it is very
important that a high-quality research trial of drug
checking in Australia be conducted.
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